Sponsors (2)
The bill encourages lower-priced, transparent production of certain drugs and devices and secures emergency stockpile access by empowering nonprofits and oversight, but it does so with funding, governance, and procurement conditions that could limit private investment, experienced staffing, and short-term supply or revenue for producers.
Patients with chronic conditions will likely pay less for certain drugs and medical devices because designated nonprofit manufacturers/distributors must prioritize affordability and cost-transparency.
Hospitals and health systems (and by extension communities during emergencies) will have improved access to critical supplies because HHS can secure at least 25% of production/stock at cost for the Strategic National Stockpile during identified needs.
Nonprofit manufacturers/distributors can retain 501(c)(3) status, enabling philanthropic funding and tax benefits to support production of lower-cost drugs/devices.
Small manufacturers, potential commercial partners, and patients may face reduced production scale and slower availability because funding restrictions and excess-benefit rules limit permissible external funding and can deter donors or private investment.
Patients and hospitals could see reduced immediate commercial supply or higher financial strain on nonprofit producers because HHS has priority access to at least 25% of production at cost, which may lower revenue for the producing organizations.
Hospitals, health systems, and manufacturers may lose operational efficiency or innovation capacity because restrictions limiting board/staff overlap with 'disqualified entities' can exclude experienced industry personnel.
Based on analysis of 2 sections of legislative text.
Introduced December 3, 2025 by Jacklyn Sheryl Rosen · Last progress December 3, 2025
Creates a new tax-exempt category for nonprofit health-care organizations whose main purpose is making certain drugs or medical devices affordable and available. Designated organizations can manufacture or distribute qualifying products and still be treated as 501(c)(3) charities, subject to application, conflict-of-interest limits, funding limits, and requirements to reserve at least 25% of production or stock at cost for HHS to supplement the Strategic National Stockpile when needed. The Treasury Secretary, in consultation with HHS, must set rules for designation, affordability and cost-transparency standards, and ongoing compliance; impermissible funding above narrow allowable categories will be treated as an excess benefit transaction. The tax changes apply to taxable years beginning one year after enactment.